Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients (AERODUO-2)

17 de noviembre de 2026 actualizado por: AeroRx Therapeutics Inc.

Randomized, Double-Blind, Placebo-Controlled, 14-Day Treatment, 2-Period Crossover Trial Evaluating the Lung Function Response After Treatment With Inhaled LABA and LAMA Monotherapies and Their Combination AERO-007 Administered Via Nebulization in Participants With Chronic Obstructive Pulmonary Disease (COPD) (AERODUO-2 Trial)

This is a phase 2b, randomized, double-blind, placebo-controlled, dose-ranging,14-day dosing, 2-period crossover study in participants with chronic obstructive pulmonary disease (COPD).

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

Combination of a long-acting beta-agonist (LABA) bronchodilator and a long-acting muscarinic antagonist (LAMA) bronchodilator is the preferred choice for initial therapy for patients with chronic obstructive pulmonary disease (COPD). Although there are currently multiple LABA+LAMA combination bronchodilators available in metered dose inhalers (MDIs), dry powder inhalers (DPI), and soft mist inhalers (SMI), a significant percentage of COPD patients, generally high risk and older patients, do not receive optimal benefit from inhalers.

Nebulized delivery provides an effective alternative where disease management is sub optimal. To date there are no approved LABA+LAMA combinations available by nebulization.

AERO-007 is a propriety inhalation solution formulation of fixed-dose combination of LABA+LAMA (indacaterol, AERO-001 and glycopyrrolate, AERO-002) for delivery in a general purpose nebulizer device. A phase 2a, single-dose, dose-ranging study of AERO-007 has been completed in participants with COPD at two dose levels (100/50 µg and 200/100 µg). AERO-007 at both low and high doses was well tolerated with robust, clinically meaningful and statistically significant bronchodilation with rapid onset of action that was sustained for 24 hours.

The objective of this phase 2b study is to determine the optimal doses of the monotherapy components of AERO-007 and to assess the safety, PK and bronchodilation profile of AERO-007 following 14 days of dosing in participants with COPD.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

64

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • London, Reino Unido
        • Reclutamiento
        • Parexel
      • Manchester, Reino Unido
        • Reclutamiento
        • Medicines Evaluation Unit

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

40 años a 75 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Male or female aged 40 to 75 years, inclusive, at the time of informed consent

  • Clinical diagnosis of COPD according to the Global Initiative for Chronic Obstructive Lung Disease [GOLD] Report, 2026 for at least 12 months prior to Screening Visit 1

  • Post-bronchodilator spirometry (after 10 to 30 minutes following 4 puffs of albuterol via MDI with a spacer) at Screening Visit 2 demonstrating the following:

    • FEV1 > 40 and < 80% of predicted normal (using the Global Lung Function Initiative [GLI] 2012 reference values)
    • FEV1/forced vital capacity (FVC) ratio < 0.70
    • ≥ 150 mL increase from pre-bronchodilator FEV1 following 4 puffs of albuterol
  • Ability to change current COPD therapy and discontinue long-acting bronchodilators, if applicable, for the duration of the trial and short-acting bronchodilators for 8 hours prior to dosing at each Treatment Visit

  • Current or former-smokers with at least 10 pack-year smoking history (eg, at least 1 pack/day for 10 years, 10 packs/day for 1 year)

  • Ability to perform reproducible spirometry according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines

  • Female participants of childbearing potential must not be pregnant, breast feeding or lactating and heterosexual female participants of childbearing potential must agree to use, with their partner, a male condom plus an approved method of highly effective birth control from the time of informed consent and for 30 days following the last administered dose

  • Female participants of childbearing potential must have a negative serum or urine pregnancy test at Screening Visit 1 and a negative urine pregnancy test prior to dosing at each Treatment Visit

  • Male participants who are sexually active with a female partner of childbearing potential must use, with their partner, a male condom plus an approved method of highly effective contraception from the time of informed consent and for 30 days following the last administered dose

  • Participants must agree not to donate semen or ova/oocytes from the time of informed consent and for 30 days following the last administered dose

  • Willing and able to provide written informed consent

Exclusion Criteria:

  • Current evidence or recent history of significant comorbidities; including cardiovascular disease (such as myocardial infarction, cardiac failure, uncontrolled hypertension, or life-threatening arrhythmias), uncontrolled diabetes, neurologic, psychiatric, hepatic, renal, immunological, or hematological conditions within the last 6 months prior to Screening Visit 1
  • Positive serum hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody or human immunodeficiency virus (HIV) type 1 and/or 2 antibodies at Screening Visit 1
  • Lower respiratory tract infection within 6 weeks prior to Screening Visit 1
  • Recent history of hospitalization due to an exacerbation of airway disease or acute worsening of COPD requiring antibiotic or systemic corticosteroid treatment within 6 months prior to Screening Visit 1
  • Other respiratory disorders: Current diagnosis of predominant asthma, lung cancer, bronchiectasis, interstitial lung disease, tuberculosis, pulmonary hypertension, or other non-specific pulmonary diseases
  • Prior lung volume reduction surgery or history of chest/lung irradiation
  • Daily oxygen therapy for > 12 hours per day
  • Body mass index >35 kg/m2
  • Abnormal and clinically significant 12-lead ECG findings at Screening Visit 1
  • Current or recent history of medical conditions that are contraindicated for use of an inhaled LAMA (such as urinary retention or bladder neck obstruction type symptoms, prostatic hypertrophy, or narrow-angle glaucoma) within the last 6 months prior to Screening Visit 1
  • Current or recent history (previous 12 months) of excessive use or abuse of alcohol (males >21 units per week and females >14 units per week)
  • Current evidence or history (within the past 2 years) of abusing legal drugs or use of illegal drugs or substances
  • Donation of 450 mL of blood within 8 weeks of Screening Visit 1
  • Major surgery (requiring general anaesthesia) within 6 weeks prior to Screening Visit 1, or planned surgery through the EOS Visit
  • History of malignancy of any organ system, except for localized skin cancers, within 5 years prior to Screening Visit 1
  • History of intolerance or hypersensitivity to any of the ingredients in the formulation for AERO-001, AERO-002, AERO-007, or other aerosol medications
  • Participation in another investigational drug trial within 30 days of the last dose, 5 half-lives or twice the duration of the biological effect, whichever is longer, prior to Screening Visit 1
  • History or high risk of noncompliance with trial visits and procedures or unsuitable for entry into the trial at the discretion of the Investigator

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación factorial
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador de placebos: Placebo

Double-blind

Experimental: Dosis baja aero-001

Double-blind

Experimental: Dosis alta aero-001

Double-blind

Experimental: Dosis baja aero-002

Double-blind

Experimental: Dosis alta aero-002

Double-blind

Experimental: AERO-001 medium dose

Double-blind

Experimental: AERO-002 medium dose

Double-blind

Experimental: AERO-007

Double-blind

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Periodo de tiempo
Bronchodilation - FEV1
Periodo de tiempo: Change from baseline in FEV1 at 24 hours post-dose on Days 1 and 14
Change from baseline in FEV1 at 24 hours post-dose on Days 1 and 14
Bronchodilation - FEV AUC
Periodo de tiempo: Change from baseline in FEV1 AUC(0-24 hours) on Days 1 and 14
Change from baseline in FEV1 AUC(0-24 hours) on Days 1 and 14
Bronchodilation - Peak FEV1
Periodo de tiempo: Peak change in FEV1 within 4 hours post-dose on Days 1 and 14
Peak change in FEV1 within 4 hours post-dose on Days 1 and 14
Bronchodilation - time to onset of FEV1 >100mL
Periodo de tiempo: Change in FEV1 >100mL from pre-dose on Days 1 and 14
Change in FEV1 >100mL from pre-dose on Days 1 and 14

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Pharmacokinetics - Cmax
Periodo de tiempo: 0-24 hours on Days 1 and 14

Cmax (maximum plasma concentration)

0-24 hours on Days 1 and 14
Pharmacokinetics - AUC
Periodo de tiempo: AUC(0-6 hours) on Days 1 and 14

AUC (area under the plasma concentration)

AUC(0-6 hours) on Days 1 and 14
Pharmacokinetics - Tmax
Periodo de tiempo: Tmax on Days 1 and 14

Tmax (time to maximum concentration)

Tmax on Days 1 and 14
Treatment-emergent adverse events (TEAEs)
Periodo de tiempo: Up to approximately Day 14

Number of participants with TEAEs

Up to approximately Day 14
Blood Pressure
Periodo de tiempo: Up to approximately Day 14

Number of participants with markedly abnormal changes in Blood Pressure

Up to approximately Day 14
Heart Rate
Periodo de tiempo: Up to approximately Day 14

Number of participants with markedly abnormal changes in Heart Rate

Up to approximately Day 14
12-lead ECG - QT Interval corrected for Heart Rate Using Fridericia's Formula (QTcF)
Periodo de tiempo: Up to approximately Day 14

Number of participants with markedly abnormal changes in QTcF

Up to approximately Day 14
Clinical laboratory - Hematology
Periodo de tiempo: Up to approximately Day 14

Number of participants with markedly abnormal changes in hematology parameters

Up to approximately Day 14
Clinical laboratory - Blood Chemistry
Periodo de tiempo: Up to approximately Day 14

Number of participants with markedly abnormal changes in blood chemistry parameters

Up to approximately Day 14

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de noviembre de 2026

Finalización primaria (Estimado)

1 de junio de 2027

Finalización del estudio (Estimado)

1 de septiembre de 2027

Fechas de registro del estudio

Enviado por primera vez

14 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

19 de octubre de 2026

Publicado por primera vez (Actual)

26 de octubre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

19 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

17 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • AERO-007-02
  • 2026-527150-39 (Número EudraCT)

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .